TRDA ENTRADA THERAPEUTICS INC revenue, earnings and financials

For the quarter ended June 30, 2026, ENTRADA THERAPEUTICS INC reported revenue of $898K (down 53.9% from a year earlier), net income of −$42.8M and diluted EPS of −$1.01; over the last four quarters revenue was $4.69M and net income −$166M; for the fiscal year ended December 2025 revenue was $25.4M, down 87.9% on the year before.

TRDA annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $25.4M, gross profit n/a, operating income −$158M, net income −$144M (margin -565.5%), EPS −$3.47
• Fiscal year ended Dec 2024: revenue $211M, gross profit n/a, operating income $47.0M, net income $65.6M (margin 31.1%), EPS $1.68
• Fiscal year ended Dec 2023: revenue $129M, gross profit n/a, operating income −$3.16M, net income −$6.69M (margin -5.2%), EPS −$0.20
• Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$97.2M, net income −$94.6M (margin n/a), EPS −$3.02
• Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$51.1M, net income −$51.2M (margin n/a), EPS −$8.16

TRDA quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $898K (down 53.9% year over year), net income −$42.8M, EPS −$1.01
• Quarter ended Mar 31, 2026: revenue $875K (down 95.7% year over year), net income −$39.7M, EPS −$0.95
• Quarter ended Dec 31, 2025 (from the annual report): revenue $1.30M (down 96.5% year over year), net income −$39.2M, EPS −$0.95
• Quarter ended Sep 30, 2025: revenue $1.61M (down 91.8% year over year), net income −$44.1M, EPS −$1.06
• Quarter ended Jun 30, 2025: revenue $1.95M (down 97.9% year over year), net income −$43.1M, EPS −$1.04
• Quarter ended Mar 31, 2025: revenue $20.6M (down 65.2% year over year), net income −$17.3M, EPS −$0.42
• Quarter ended Dec 31, 2024 (from the annual report): revenue $37.4M (down 10.6% year over year), net income $1.13M, EPS −$0.20
• Quarter ended Sep 30, 2024: revenue $19.6M (down 55.3% year over year), net income −$14.0M, EPS −$0.35
• Quarter ended Jun 30, 2024: revenue $94.7M (up 421.2% year over year), net income $55.0M, EPS $1.55
• Quarter ended Mar 31, 2024: revenue $59.1M (up 134.0% year over year), net income $23.5M, EPS $0.68
• Quarter ended Dec 31, 2023 (from the annual report): revenue $41.8M, net income −$9.54M, EPS −$0.23
• Quarter ended Sep 30, 2023: revenue $43.7M, net income $35.5M, EPS $1.02
• Quarter ended Jun 30, 2023: revenue $18.2M, net income −$25.9M, EPS −$0.78
• Quarter ended Mar 31, 2023: revenue $25.3M, net income −$6.67M, EPS −$0.21
• Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$24.6M, EPS −$0.79
• Quarter ended Sep 30, 2022: revenue $0, net income −$25.1M, EPS −$0.80
• Quarter ended Jun 30, 2022: revenue $0, net income −$23.2M, EPS −$0.74
• Quarter ended Mar 31, 2022: revenue $0, net income −$21.7M, EPS −$0.69
• Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$18.4M, EPS $15.85
• Quarter ended Sep 30, 2021: revenue n/a, net income −$14.4M, EPS −$9.78

TRDA cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$129M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$41.6M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow $140M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$93.8M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$50.9M, share buybacks n/a

TRDA balance sheet

• Jun 30, 2026: cash $99.3M, total assets $299M, total liabilities $65.5M, shareholders' equity $233M
• Mar 31, 2026: cash $76.4M, total assets $336M, total liabilities $64.7M, shareholders' equity $271M
• Dec 31, 2025: cash $90.4M, total assets $377M, total liabilities $71.2M, shareholders' equity $306M
• Sep 30, 2025: cash $93.3M, total assets $413M, total liabilities $72.2M, shareholders' equity $341M
• Jun 30, 2025: cash $72.5M, total assets $449M, total liabilities $69.3M, shareholders' equity $380M
• Mar 31, 2025: cash $67.8M, total assets $486M, total liabilities $69.2M, shareholders' equity $417M
• Dec 31, 2024: cash $101M, total assets $526M, total liabilities $97.6M, shareholders' equity $429M
• Sep 30, 2024: cash $78.0M, total assets $555M, total liabilities $132M, shareholders' equity $422M

What is TRDA's revenue?

ENTRADA THERAPEUTICS INC reported $4.69M of revenue over its last four quarters, through June 30, 2026.

Is TRDA profitable?

No. ENTRADA THERAPEUTICS INC lost $166M over the last four quarters.

What is TRDA's EPS?

Diluted earnings per share over the last four quarters were −$3.97; −$1.01 in the latest quarter.

TRDA ownership and insider trades · All stocks